Written by the people
who built the platform.
Practitioners with decades inside pharma, regulatory, and clinical operations. Not marketing copy. Actual perspectives on what is changing and why.
Featured article
Data Integrity, AI Governance and Quality-by-Design Compliance After FDA's 2026 Guidance
The FDA 2024 data integrity guidance and the January 2026 AI principles make one thing clear: data integrity is no longer a GxP checkbox. It is the foundational requirement that determines whether your AI systems are even allowed to operate in a regulated trial environment.
All articles
Why eClinical Integration Is the Fastest-Growing Segment in Clinical Software
The eClinical integration market grows at 17.54% CAGR. Here is what is driving it, where the consolidation is heading, and why C2TA (Clinical-to-Trial Activity) sits at the centre of the next 5 years.
How SARA AI Is Changing Real-Time Trial Quality Monitoring in 2026
SARA AI processes the data volume that human monitoring cannot keep up with in real time. Here is what that looks like in a live trial environment.
Why Excel-Based EDC Still Runs 40% of Trials and What It Actually Costs
The IGMCRI comparison was a controlled observation. Same protocol, same sites, same compliance requirements. The only change was the EDC platform.
C2TA and the Regulatory Question Nobody Is Asking About Patient Payments
The FDA has guidance on undue influence in clinical trial compensation. Most platforms create the conditions for undue influence by accident, through payment delays that make lump-sum offers feel necessary.
What FDA's January 2026 AI Principles Mean for eClinical Platform Selection
The principles are clear: AI in a regulated clinical environment must be explainable, auditable, and operator-controlled. Most platforms calling themselves AI-enabled fail two of those three requirements.
The C2TA Window: Why Integrated Trial Finance Has 18 Months Before the Market Consolidates
Suvoda and Greenphire are building toward integration. The window to establish C2TA as the standard for integrated clinical trial payment is 12 to 18 months. Here is the market map.
FDA updates. Market shifts.
Practical clinical operations.
Once a month. Written by the Chief Scientific Officer and CEO. No product announcements dressed up as content.